The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

0.05%Dividend Yield

Dec 2025

$0.02

Dec 2024

$0.73

Dec 2023

$0.15

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

-97.31%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANC. It's not an investment recommendation.

NEOS Nasdaq 100 High Income

QQQI

Schwab U.S. Large-Cap Growth

SCHG

iShares 0-3 Month Treasury Bond

SGOV

Goldman Sachs Nasdaq-100 Premium Income

GPIQ

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

BMY

Mkt Cap127.71B

Bristol-Myers Squibb is a major player in the oncology sector, developing similar cancer treatments and therapies.

Merck

MRK

Mkt Cap368.89B

Merck is known for its strong portfolio in cancer drugs, directly competing in the oncology market.

Pfizer

PFE

Mkt Cap173.95B

Pfizer has a significant presence in oncology through its various cancer treatment solutions.

Novartis

NVS

Mkt Cap303.67B

Novartis offers a broad range of oncology products that compete in similar therapeutic areas as Tema Oncology.

Roche

RHHBY

Mkt Cap334.28B

Roche Holding AG is a leader in oncology, particularly in cancer immunotherapy, competing directly with Tema Oncology.

Astrazeneca

AZN

Mkt Cap289.48B

AstraZeneca has a strong focus on oncology, with numerous cancer drugs that compete with Tema Oncology's offerings.

AMGEN

AMGN

Mkt Cap251.94B

Amgen focuses on human therapeutics, including oncology, where it competes with Tema Oncology in cancer treatment.

Gilead Sciences

GILD

Mkt Cap211.7B

Gilead Sciences is involved in the development of oncology products, particularly in areas overlapping with Tema Oncology's focus.

Regeneron Pharmaceuticals

REGN

Mkt Cap75.69B

Regeneron Pharmaceuticals is engaged in the discovery of cancer treatments, competing in the oncology space.

Holdings

Regions

Sectors

About

The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.

CEO

Country

United States

ISIN

US87975E7013

Listings

0 Comments

Share your thoughts

FAQs

What is Tema Oncology stock price today?▼

The current price of CANC is $42.29 USD — it has decreased by -0.15% in the past 24 hours. Watch Tema Oncology stock price performance more closely on the chart.

What is Tema Oncology stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tema Oncology stocks are traded under the ticker CANC.

Is Tema Oncology stock price growing?▼

CANC stock has risen by +3.18% compared to the previous week, the month change is a +3.17% rise, over the last year Tema Oncology has showed a +36.51% increase.

Does Tema Oncology pay dividends?▼

Yes, CANC dividends are paid annual. The last dividend per share was 0.02 . As of today, Dividend Yield (FWD)% is 0.05%.

In which sector is Tema Oncology located?▼

Tema Oncology operates in the Finance & Payments sector.

When did Tema Oncology complete a stock split?▼

Tema Oncology has not had any recent stock splits.

Where is Tema Oncology headquartered?▼

Tema Oncology is headquartered in New York, United States.